Structure via PubChem · Public domain (PubChem)
pimavanserin
Sign in to saveAlso known as ACP 103, ACP-103
Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. It is taken by mouth.
Key facts
- Drug.Verifiedfields
- verified
- Drug.Watchedfields
- verified
- Drug.verifiedrevid
- 448227829
- Drug.image
- Pimavanserin structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250px
- Drug.tradename
- Nuplazid
- Drug.DailyMedID
- Pimavanserin
- Drug.routes_of_administration
- Oral
- Drug.class
- Serotonin 5-HT2A receptor antagonist; Antipsychotic
- Drug.ATC_prefix
- N05
- Drug.ATC_suffix
- AX17
- Drug.legal_US
- Rx-only
- Drug.protein_bound
- 94–97%
- Drug.metabolism
- Hepatic (CYP3A4, CYP3A5, CYP2J2)
- Drug.metabolites
- N-Desmethyl-pimavanserin
- Drug.onset
- 6 hours
- Drug.elimination_half life
- Pimavanserin: 54–57hN-Desmethyl-pimavanserin (active): 200h
via Wikipedia infobox
Chemical data
- Formula
- C25H34FN3O2
- Molecular weight
- 427.6 g/mol
- IUPAC name
- 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
- SMILES
- CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C
- InChIKey
- RKEWSXXUOLRFBX-UHFFFAOYSA-N
- XLogP
- 4.5
- Polar surface area
- 44.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2016
- Admin. routes
- oral
- Indications
- psychosis, neurodegenerative disease, major depressive disorder, Tourette syndrome
via ChEMBL · EBI
Research
407 papers- Pimavanserin.2012
- Trial of Pimavanserin in Dementia-Related Psychosis.The New England journal of medicine · 2021
- Pimavanserin.Drugs of today (Barcelona, Spain : 1998) · 2015
- Pimavanserin.2006
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.Lancet (London, England) · 2014
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 427.263506
Show 4 more facts
- medical condition treated
- Parkinson's disease
- chemical formula
- C₂₅H₃₄FN₃O₂
- canonical SMILES
- CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C
- Commons category
- Pimavanserin
via Wikidata · CC0
~7 min read
Encyclopedic overview
14 sectionsContents
- Medical uses
- Available forms
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- History
- Development
- FDA Approval
- HARMONY-Trial
- Controversy
- Research
- See also
- References
Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. It is taken by mouth.
Side effects of pimavanserin include peripheral edema and confusion. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist, but rather is a selective antagonist or inverse agonist of the serotonin 5-HT2A receptor and to a lesser extent of the serotonin 5-HT2C receptor.
Excerpted from Wikipedia’s “pimavanserin” article, available under the CC BY-SA 4.0 licence.